Spots Global Cancer Trial Database for bcg
Every month we try and update this database with for bcg cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Combined Use of BCG and Interferon Alpha in Bladder Cancer | NCT00330707 | Carcinoma of Ur... | Bacillus Calmet... | 18 Years - | National University Hospital, Singapore | |
| Efficacy of Diclofenac BCG Irrigations | NCT01542567 | Bladder Cancer | Abitren Placebo | 20 Years - 80 Years | Carmel Medical Center | |
| Efficacy of Diclofenac BCG Irrigations | NCT01542567 | Bladder Cancer | Abitren Placebo | 20 Years - 80 Years | Carmel Medical Center | |
| A Study of Rapamycin Combined With Intravesical BCG in Patients With Non-muscle Invasive Bladder Cancer | NCT02753309 | Bladder Cancer | Sirolimus | 18 Years - | The University of Texas Health Science Center at San Antonio | |
| Mitomycin C Intravesical Chemotherapy in Conjunction With Synergo® Radiofrequency-Induced Hyperthermia for Treatment of Carcinoma in Situ Non-Muscle Invasive Bladder Cancer Patients Unresponsive to Bacillus Calmette-Guérin, With or Without Papillary Tumors. | NCT03335059 | Bladder Cancer Bladder Neoplas... Bladder Tumors Cancer of Bladd... Cancer of the B... Malignant Tumor... Neoplasms, Blad... Urinary Bladder... Carcinoma in Si... Papillary Carci... BCG-Unresponsiv... | Synergo® RITE +... | 18 Years - | Medical Enterprises Ltd. | |
| Avelumab Plus Bacille Calmette-Guerin (BCG) in Patients With Non-muscle Invasive Bladder Cancer | NCT03892642 | Bladder Cancer | Avelumab BCG | 18 Years - | University of Oklahoma | |
| Atezolizumab and BCG in High Risk BCG naïve Non-muscle Invasive Bladder Cancer (NMIBC) Patients (BladderGATE) | NCT04134000 | Invasive Bladde... | Atezolizumab BCG | 18 Years - | Fundacion Oncosur | |
| A New Prognostic Model for Predicting the Outcome of Patients With Non-muscle Invasive Bladder Cancer (NMIBC) | NCT03121768 | Oncology Bladder Cancer Superficial Bla... Recurrence Progression BCG | 18 Years - | Mansoura University | ||
| A Study of Nivolumab or Nivolumab Plus Experimental Medication BMS-986205 With or Without Bacillus Calumette-Guerin (BCG) in BCG Unresponsive Bladder Cancer That Has Not Invaded Into the Muscle Wall of the Bladder | NCT03519256 | Urinary Bladder... | Nivolumab BCG BMS-986205 | 18 Years - | Bristol-Myers Squibb | |
| Immunological Response of Bladder Cancer Patients Under BCG | NCT04806178 | Bladder Cancer Bacillus Calmet... | Bacillus Calmet... PLACEBO | 18 Years - | University of Campinas, Brazil | |
| Propranolol Adjuvant Treatment of Bladder Cancer | NCT04493489 | Bladder Cancer | Propranolol Hyd... BCG | 18 Years - 75 Years | Central South University | |
| Antegrade Observational Comparative Study for the Intravesical Instillation Therapy of Bacillus Calmette Guerin With the Use of Different Types of Urinary Catheters in Patients With Urinary Bladder Cancer | NCT05675176 | Non-muscle-inva... | BCG | - | National and Kapodistrian University of Athens | |
| Study of the Efficacy of Maintenance Therapy Using Uracil-tegafur (UFT) or Bacille Calmette-Guerin (BCG) for the Prevention of Recurrences of Superficial Bladder Cancer (EMBARK Study) | NCT01082510 | Bladder Cancer | Bacille Calmett... uracil-tegafur | 20 Years - 80 Years | Urological Oncology Council of Northern Tokyo | |
| Sequential Bacillus Calmette-Guérin (BCG) and Electromotive Mitomycin-C Versus Bacillus Calmette-Guérin (BCG) Alone for High Risk Superficial Bladder Cancer | NCT01442519 | Bladder Cancer | bacillus Calmet... electromotive m... | 18 Years - 90 Years | University of Rome Tor Vergata | |
| QUILT-3.032: A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 (N-803) in Patients With BCG Unresponsive High Grade Non-Muscle Invasive Bladder Cancer | NCT03022825 | Bladder Cancer | N-803 and BCG N-803 | 18 Years - | ImmunityBio, Inc. | |
| BCG Modulation of the recMAGE-A3 + AS15 ASCI Response in the Treatment of Non Muscle Invasive Bladder Cancer (NMIBC) Patients | NCT01498172 | Bladder Cancer | MAGE-A3 ASCI BCG | 18 Years - | University of Lausanne Hospitals | |
| Phase I Study of Intralesional Bacillus Calmette-Guerin (BCG) Followed by Ipilimumab in Advanced Metastatic Melanoma | NCT01838200 | Metastatic Mela... | Bacillus Calmet... Ipilimumab Isoniazid | 18 Years - | Ludwig Institute for Cancer Research | |
| BCG in Combination With Durvalumab in Adult BCG-naïve, High-risk NMIBC Participants | NCT05943106 | Non-Muscle- Inv... | Durvalumab BCG | 18 Years - 130 Years | AstraZeneca | |
| Retrospective Chart Review of Valstar | NCT01304173 | Carcinoma in Si... | 18 Years - | Endo Pharmaceuticals | ||
| Safety and Efficacy Study of Tislelizumab in Combination With BCG in HR-NMIBC Patients (TACBIN-01) | NCT04922047 | Urinary Bladder... Urologic Neopla... Urogenital Neop... Antineoplastic ... Urinary Bladder... Tislelizumab An... | tislelizumab an... | 18 Years - 75 Years | RenJi Hospital | |
| Phase I Mitomycin Combined With Bacillus Calmette-Guérin (BCG) for Bladder Cancer | NCT02311101 | Urinary Bladder... | Mitomycin C | 18 Years - | The University of Texas Health Science Center at San Antonio | |
| Phase I Mitomycin Combined With Bacillus Calmette-Guérin (BCG) for Bladder Cancer | NCT02311101 | Urinary Bladder... | Mitomycin C | 18 Years - | The University of Texas Health Science Center at San Antonio | |
| Role of Microbiome in BCG Responsiveness Prediction | NCT05204199 | Microbiome Bladder Cancer | 18 Years - 90 Years | University of Zurich | ||
| Phase I Mitomycin Combined With Bacillus Calmette-Guérin (BCG) for Bladder Cancer | NCT02311101 | Urinary Bladder... | Mitomycin C | 18 Years - | The University of Texas Health Science Center at San Antonio | |
| Assessment of Efficacy and Safety of Durvalumab Plus BCG Compared to the Standard Therapy With BCG in Non-muscle Invasive Bladder Cancer | NCT03528694 | Non-muscle-inva... | Durvalumab (MED... Bacillus Calmet... | 18 Years - 130 Years | AstraZeneca | |
| BCG Modulation of the recMAGE-A3 + AS15 ASCI Response in the Treatment of Non Muscle Invasive Bladder Cancer (NMIBC) Patients | NCT01498172 | Bladder Cancer | MAGE-A3 ASCI BCG | 18 Years - | University of Lausanne Hospitals | |
| Electromotive Mitomycin-C (EMDA-MMC) in Preventing Recurrences in High-risk Non-muscle-invasive Bladder Cancer | NCT03664869 | Bladder Cancer | BCG instillatio... Sequential BCG ... | 18 Years - | Turku University Hospital | |
| Trial of Intravesical Measles Virotherapy in Patients With Bladder Cancer Who Are Undergoing Radical Cystectomy | NCT03171493 | Urothelial Carc... | MV-NIS | 18 Years - | Vyriad, Inc. | |
| A Phase 1b/2 Clinical Trial to Evaluate the Safety and Efficacy of ConvitVax in Metastatic Breast Cancer | NCT06023277 | Metastatic Brea... | ConvitVax | 18 Years - | Jacinto Convit World Organization Inc. | |
| Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676) | NCT03711032 | High-risk Non-m... | Pembrolizumab BCG | 18 Years - | Merck Sharp & Dohme LLC | |
| Safety and Efficacy of BCG Combined With Tislelizumab for BCG-untreated Patients With High-risk Non-muscle Invasive Bladder Cancer | NCT05580354 | Non-muscle-inva... | BCG combined wi... | 18 Years - 75 Years | Ruijin Hospital | |
| Efficacy of Diclofenac BCG Irrigations | NCT01542567 | Bladder Cancer | Abitren Placebo | 20 Years - 80 Years | Carmel Medical Center | |
| Sequential Bacillus Calmette-Guérin (BCG) and Electromotive Mitomycin-C Versus Bacillus Calmette-Guérin (BCG) Alone for High Risk Superficial Bladder Cancer | NCT01442519 | Bladder Cancer | bacillus Calmet... electromotive m... | 18 Years - 90 Years | University of Rome Tor Vergata | |
| A Study of Sasanlimab in People With Non-muscle Invasive Bladder Cancer | NCT04165317 | Non-muscle Inva... | PF-06801591 Bacillus Calmet... | 18 Years - | Pfizer | |
| A New Prognostic Model for Predicting the Outcome of Patients With Non-muscle Invasive Bladder Cancer (NMIBC) | NCT03121768 | Oncology Bladder Cancer Superficial Bla... Recurrence Progression BCG | 18 Years - | Mansoura University | ||
| Safety and Efficacy of Scheduled Intravesical Gemcitabine Versus Intravesical BCG for Intermediate and High Risk Non Muscle Invasive Bladder Cancer: A Prospective, Randomized Study | NCT05626101 | Non-muscle-inva... | BCG Gemcitabine | - | Al-Azhar University | |
| Neutrophils to Lymphocytes Ratio in Predicting the Response to BCG in Non-muscle Invasive Bladder Cancer | NCT05946369 | Urinary Bladder... Urinary Bladder... BCG Trans Urethral ... Non-Muscle Inva... | Neutrophil to l... | - | Ain Shams University | |
| Bacillus of Calmette and Guerin (BCG) Versus Gemcitabine For Intravesical Therapy In High Risk Superficial Bladder Cancer | NCT00696579 | Bladder Cancer | BCG gemcitabine | 18 Years - 75 Years | University Of Perugia | |
| A Phase 1/2 Study of HS-410 in Patients With Non-Muscle Invasive Bladder Cancer After TURBT | NCT02010203 | Bladder Cancer | HS-410 Placebo BCG | 18 Years - | Heat Biologics | |
| Markers of Response to Intravesical Bladder Cancer Therapy | NCT01007058 | Bladder Cancer | 18 Years - | M.D. Anderson Cancer Center | ||
| Influence of Hyaluronic Acid on Bacillus Calmette-Guérin Local Side Effects | NCT02207608 | Poisoning by BC... | Hyaluronic Acid BCG (Immucist®) | 18 Years - | University of Rome Tor Vergata | |
| A Phase 1/2 Study of HS-410 in Patients With Non-Muscle Invasive Bladder Cancer After TURBT | NCT02010203 | Bladder Cancer | HS-410 Placebo BCG | 18 Years - | Heat Biologics | |
| Avelumab Plus Bacille Calmette-Guerin (BCG) in Patients With Non-muscle Invasive Bladder Cancer | NCT03892642 | Bladder Cancer | Avelumab BCG | 18 Years - | University of Oklahoma | |
| Mitomycin C Intravesical Chemotherapy in Conjunction With Synergo® Radiofrequency-Induced Hyperthermia for Treatment of Carcinoma in Situ Non-Muscle Invasive Bladder Cancer Patients Unresponsive to Bacillus Calmette-Guérin, With or Without Papillary Tumors. | NCT03335059 | Bladder Cancer Bladder Neoplas... Bladder Tumors Cancer of Bladd... Cancer of the B... Malignant Tumor... Neoplasms, Blad... Urinary Bladder... Carcinoma in Si... Papillary Carci... BCG-Unresponsiv... | Synergo® RITE +... | 18 Years - | Medical Enterprises Ltd. | |
| Safety and Efficacy of Scheduled Intravesical Gemcitabine Versus Intravesical BCG for Intermediate and High Risk Non Muscle Invasive Bladder Cancer: A Prospective, Randomized Study | NCT05626101 | Non-muscle-inva... | BCG Gemcitabine | - | Al-Azhar University | |
| Propranolol Adjuvant Treatment of Bladder Cancer | NCT04493489 | Bladder Cancer | Propranolol Hyd... BCG | 18 Years - 75 Years | Central South University | |
| BCG Modulation of the recMAGE-A3 + AS15 ASCI Response in the Treatment of Non Muscle Invasive Bladder Cancer (NMIBC) Patients | NCT01498172 | Bladder Cancer | MAGE-A3 ASCI BCG | 18 Years - | University of Lausanne Hospitals | |
| Safety and Efficacy of Scheduled Intravesical Gemcitabine Versus Intravesical BCG for Intermediate and High Risk Non Muscle Invasive Bladder Cancer: A Prospective, Randomized Study | NCT05626101 | Non-muscle-inva... | BCG Gemcitabine | - | Al-Azhar University |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
